Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Conditions
Interventions
Bentracimab (PB2452) Infusion
Locations
68
United States
University of Florida Health, Jacksonville
Jacksonville, Florida, United States
University of Kentucky
Lexington, Kentucky, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
Henry Ford Hospital
Detroit, Michigan, United States
North Kansas City Hospital
North Kansas City, Missouri, United States
Cox Medical Centers
Springfield, Missouri, United States
Start Date
July 15, 2020
Primary Completion Date
September 9, 2024
Completion Date
September 9, 2024
Last Updated
October 21, 2024
NCT05548530
NCT07466719
NCT07458880
NCT07455201
NCT06725108
NCT06484374
Lead Sponsor
SFJ Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions